These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

652 related items for PubMed ID: 12872340

  • 1. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C.
    Cancer; 2003 Jul 15; 98(2):229-38. PubMed ID: 12872340
    [Abstract] [Full Text] [Related]

  • 2. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
    Xu B, Jiang Z, Shao Z, Wang J, Feng J, Song S, Chen Z, Gu K, Yu S, Zhang Y, Wang C, Zhang F, Yang J.
    Cancer Chemother Pharmacol; 2011 Jan 15; 67(1):223-30. PubMed ID: 20938664
    [Abstract] [Full Text] [Related]

  • 3. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A.
    J Clin Oncol; 2002 Aug 15; 20(16):3386-95. PubMed ID: 12177098
    [Abstract] [Full Text] [Related]

  • 4. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C.
    J Clin Oncol; 2002 Aug 15; 20(16):3396-403. PubMed ID: 12177099
    [Abstract] [Full Text] [Related]

  • 5. Time to response: comparison of fulvestrant and oral endocrine agents.
    Dodwell D, Pippen J.
    Clin Breast Cancer; 2006 Aug 15; 7(3):244-7. PubMed ID: 16942641
    [Abstract] [Full Text] [Related]

  • 6. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I, Robertson JF.
    Br J Cancer; 2004 Mar 15; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [Abstract] [Full Text] [Related]

  • 7. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
    Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF.
    Cancer; 2005 Jul 15; 104(2):236-9. PubMed ID: 15937908
    [Abstract] [Full Text] [Related]

  • 8. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A.
    Breast Cancer Res Treat; 2004 Jun 15; 85(3):247-54. PubMed ID: 15111763
    [Abstract] [Full Text] [Related]

  • 9. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A.
    Cancer; 1997 Feb 15; 79(4):730-9. PubMed ID: 9024711
    [Abstract] [Full Text] [Related]

  • 10. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K, Curran MP, Plosker GL.
    Drugs; 2004 Feb 15; 64(6):633-48. PubMed ID: 15018596
    [Abstract] [Full Text] [Related]

  • 11. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D.
    Cancer; 1998 Sep 15; 83(6):1142-52. PubMed ID: 9740079
    [Abstract] [Full Text] [Related]

  • 12. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
    Yardley DA, Burris HA, Clark BL, Shipley D, Rubin M, Barton J, Arrowsmith E, Hainsworth JD.
    Clin Breast Cancer; 2011 Jun 15; 11(3):146-52. PubMed ID: 21665134
    [Abstract] [Full Text] [Related]

  • 13. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.
    Catania C, Ascione G, Adamoli L, De Pas T, Medici M, Franceschelli L, Verri E, Magni E, Sanna G, Torrisi R, Goldhirsch A, Nolè F.
    Breast Cancer Res Treat; 2007 Nov 15; 106(1):97-103. PubMed ID: 17260095
    [Abstract] [Full Text] [Related]

  • 14. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R.
    Breast Cancer Res Treat; 2007 Nov 15; 106(1):105-12. PubMed ID: 17295045
    [Abstract] [Full Text] [Related]

  • 15. Fulvestrant in postmenopausal women with advanced breast cancer.
    Bross PF, Baird A, Chen G, Jee JM, Lostritto RT, Morse DE, Rosario LA, Williams GM, Yang P, Rahman A, Williams G, Pazdur R.
    Clin Cancer Res; 2003 Oct 01; 9(12):4309-17. PubMed ID: 14555500
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5108-16. PubMed ID: 15998903
    [Abstract] [Full Text] [Related]

  • 17. Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
    Gong DD, Man CF, Xu J, Fan Y.
    Asian Pac J Cancer Prev; 2014 Aug 01; 15(5):2095-100. PubMed ID: 24716940
    [Abstract] [Full Text] [Related]

  • 18. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ.
    Lancet; 2016 Dec 17; 388(10063):2997-3005. PubMed ID: 27908454
    [Abstract] [Full Text] [Related]

  • 19. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL, Owers R, Robertson JF.
    Endocr Relat Cancer; 2006 Mar 17; 13(1):251-5. PubMed ID: 16601292
    [Abstract] [Full Text] [Related]

  • 20. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA, North Central Cancer Treatment Group Trial N0032.
    J Clin Oncol; 2006 Mar 01; 24(7):1052-6. PubMed ID: 16505423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.